Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis.
Expert Rev Pharmacoecon Outcomes Res. 2010 Aug; 10(4):359-66.ER

Abstract

Strontium ranelate has been introduced recently for the prevention and treatment of osteoporosis in Europe and in many countries worldwide. This article reviews the published cost-effectiveness literature pertaining to strontium ranelate. Six studies were identified: two in the UK, two in Belgium and two in Sweden. The findings were consistent across the literature, suggesting that strontium ranelate is a cost-saving drug for women with osteoporosis aged over 80 years, and it is a cost-effective treatment compared with no treatment for osteoporotic women aged over 70 years and for younger women with clinical risk factors for fragility fracture. Strontium ranelate was also shown to be cost effective compared with branded risedronate in osteoporotic women aged over 75 years. Further analyses are required to assess the effectiveness and adherence to strontium ranelate in real-life settings, as well as to evaluate the cost-effectiveness of strontium ranelate in other countries and in populations of men.

Authors+Show Affiliations

Pharmacoeconomics Unit Research, HEC-School of Management, University of Liège, Avenue de l'hôpital 3, Bat B23, 4000 Liège, Belgium. m.hiligsmann@ulg.ac.beNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20715911

Citation

Hiligsmann, Mickaël, et al. "Cost-effectiveness of Strontium Ranelate for the Prevention and Treatment of Osteoporosis." Expert Review of Pharmacoeconomics & Outcomes Research, vol. 10, no. 4, 2010, pp. 359-66.
Hiligsmann M, Vanoverberghe M, Neuprez A, et al. Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. Expert Rev Pharmacoecon Outcomes Res. 2010;10(4):359-66.
Hiligsmann, M., Vanoverberghe, M., Neuprez, A., Bruyère, O., & Reginster, J. Y. (2010). Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. Expert Review of Pharmacoeconomics & Outcomes Research, 10(4), 359-66. https://doi.org/10.1586/erp.10.53
Hiligsmann M, et al. Cost-effectiveness of Strontium Ranelate for the Prevention and Treatment of Osteoporosis. Expert Rev Pharmacoecon Outcomes Res. 2010;10(4):359-66. PubMed PMID: 20715911.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. AU - Hiligsmann,Mickaël, AU - Vanoverberghe,Marie, AU - Neuprez,Audrey, AU - Bruyère,Olivier, AU - Reginster,Jean-Yves, PY - 2010/8/19/entrez PY - 2010/8/19/pubmed PY - 2010/12/14/medline SP - 359 EP - 66 JF - Expert review of pharmacoeconomics & outcomes research JO - Expert Rev Pharmacoecon Outcomes Res VL - 10 IS - 4 N2 - Strontium ranelate has been introduced recently for the prevention and treatment of osteoporosis in Europe and in many countries worldwide. This article reviews the published cost-effectiveness literature pertaining to strontium ranelate. Six studies were identified: two in the UK, two in Belgium and two in Sweden. The findings were consistent across the literature, suggesting that strontium ranelate is a cost-saving drug for women with osteoporosis aged over 80 years, and it is a cost-effective treatment compared with no treatment for osteoporotic women aged over 70 years and for younger women with clinical risk factors for fragility fracture. Strontium ranelate was also shown to be cost effective compared with branded risedronate in osteoporotic women aged over 75 years. Further analyses are required to assess the effectiveness and adherence to strontium ranelate in real-life settings, as well as to evaluate the cost-effectiveness of strontium ranelate in other countries and in populations of men. SN - 1744-8379 UR - https://www.unboundmedicine.com/medline/citation/20715911/Cost_effectiveness_of_strontium_ranelate_for_the_prevention_and_treatment_of_osteoporosis_ DB - PRIME DP - Unbound Medicine ER -